HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on TG Therapeutics (NASDAQ:TGTX) and maintains a $34 price target.
May 31, 2023 | 1:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on TG Therapeutics and maintains a $34 price target.
The reiterated Buy rating and maintained $34 price target by HC Wainwright & Co. analyst Edward White indicates a positive outlook for TG Therapeutics. This news is likely to have a positive short-term impact on the stock price as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100